Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Nurix Therapeutics Inc.

    NASDAQ: NRIX · Real-Time Price · USD
    11.87
    -0.06 (-0.50%)
    At close: Jun 16, 2025, 3:59 PM
    11.91
    0.34%
    After-hours: Jun 16, 2025, 04:20 PM EDT

    Nurix Therapeutics Statistics

    Share Statistics

    Nurix Therapeutics has 76.24M shares outstanding. The number of shares has increased by 17.92% in one year.

    Shares Outstanding

    n/a
    		 76.24M

    Shares Change (YoY)

    n/a
    		 17.92%

    Shares Change (QoQ)

    n/a
    		 7.13%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 74.71M

    Failed to Deliver (FTD) Shares

    n/a
    		 258

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 14.09M, so 18.48% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 14.09M

    Short % of Shares Out

    n/a
    		 18.48%

    Short % of Float

    n/a
    		 21.72%

    Short Ratio (days to cover)

    n/a
    		 18.28

    Valuation Ratios

    The PE ratio is -7.67 and the forward PE ratio is -3.73. Nurix Therapeutics's PEG ratio is -0.88.

    PE Ratio

    n/a
    		 -7.67

    Forward PE

    n/a
    		 -3.73

    PS Ratio

    n/a
    		 27.21

    Forward PS

    n/a
    		 2.3

    PB Ratio

    n/a
    		 2.82

    P/FCF Ratio

    n/a
    		 -8.16

    PEG Ratio

    n/a
    		 -0.88
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Nurix Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.05.

    Current Ratio

    n/a
    		 6.46

    Quick Ratio

    n/a
    		 6.46

    Debt / Equity

    n/a
    		 0.05

    Debt / EBITDA

    n/a
    		 -0.14

    Debt / FCF

    n/a
    		 -0.16

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $190,730.77

    Profits Per Employee

    n/a
    		 $-676,814.69

    Employee Count

    n/a
    		 286

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 270K

    Effective Tax Rate

    n/a
    		 -0.14%

    Stock Price Statistics

    The stock price has increased by -22.37% in the last 52 weeks. The beta is 2.16, so Nurix Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.16

    52-Week Price Change

    n/a
    		 -22.37%

    50-Day Moving Average

    n/a
    		 10.65

    200-Day Moving Average

    n/a
    		 17.97

    Relative Strength Index (RSI)

    n/a
    		 56.42

    Average Volume (20 Days)

    n/a
    		 996,823

    Income Statement

    In the last 12 months, Nurix Therapeutics had revenue of 54.55M and earned -193.57M in profits. Earnings per share was -2.88.

    Revenue

    n/a
    		 54.55M

    Gross Profit

    n/a
    		 38.12M

    Operating Income

    n/a
    		 -213.03M

    Net Income

    n/a
    		 -193.57M

    EBITDA

    n/a
    		 -196.6M

    EBIT

    n/a
    		 -213.03M

    Earnings Per Share (EPS)

    n/a
    		 -2.88
    Full Income Statement

    Balance Sheet

    The company has 110M in cash and 28.3M in debt, giving a net cash position of 81.69M.

    Cash & Cash Equivalents

    n/a
    		 110M

    Total Debt

    n/a
    		 28.3M

    Net Cash

    n/a
    		 81.69M

    Retained Earnings

    n/a
    		 -738.77M

    Total Assets

    n/a
    		 615.04M

    Working Capital

    n/a
    		 473.71M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -172.58M and capital expenditures -9.27M, giving a free cash flow of -181.86M.

    Operating Cash Flow

    n/a
    		 -172.58M

    Capital Expenditures

    n/a
    		 -9.27M

    Free Cash Flow

    n/a
    		 -181.86M

    FCF Per Share

    n/a
    		 -2.71
    Full Cash Flow Statement

    Margins

    Gross margin is 69.88%, with operating and profit margins of -390.52% and -354.85%.

    Gross Margin

    n/a
    		 69.88%

    Operating Margin

    n/a
    		 -390.52%

    Pretax Margin

    n/a
    		 -354.36%

    Profit Margin

    n/a
    		 -354.85%

    EBITDA Margin

    n/a
    		 -360.41%

    EBIT Margin

    n/a
    		 -390.52%

    FCF Margin

    n/a
    		 -333.38%

    Dividends & Yields

    NRIX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NRIX is $31, which is 161.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $31

    Price Target Difference

    n/a
    		 161.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 16
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.57

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist